Faxitron Receives Regulatory Approval to Offer Digital Specimen Radiography Systems in Brazil
Posted: 2013-3-21
Faxitron today announced that the Brazilian National Health Surveillance Agency
ANVISA (Agencia Nacional de Vigilancia Sanitaria) has approved their leading-
edge technology for clinical use and commercialization in Brazil. Faxitron's
Intraoperative Specimen Radiography System, BioVision, and Stereotactic Core
Biopsy Specimen Radiography System, CoreVision, greatly enhance the standard
of patient care and improve operational efficiency in the diagnosis of breast
cancer.
Paul Murtagh, Faxitron’s CEO, stated: "The ANVISA medical device certification
allows us to play a central role in the critical ‘standard of care’ chain in breast
cancer. Our products enable radiologists and pathologists to diagnose more
quickly and surgeons to operate more efficiently. We are thrilled to be able to
bring our technology to Brazil to support opinion leading institutions and their
patients".
Brazil has the largest economy and medical device market in Latin America, and
there is an ever growing need for specialized imaging technology such as the
BioVision and CoreVision to improve the overall quality of care for the patients.
About Faxitron
Faxitron is the world’s largest and only fully vertically integrated, dedicated
cabinet x-ray company. With an installed base of over 7,000 systems in medical
facilities and scientific and industrial research laboratories around the globe,
Faxitron is the pioneer and industry standard in cabinet x-ray systems for
specimen radiography, research, and NDT applications. For more than 40 years,
Faxitron has defined cabinet x-ray by developing x-ray sensor technology and
innovative systems to meet the evolving needs of our customers. For more
information, please visit http://www.faxitron.com.
ANVISA (Agencia Nacional de Vigilancia Sanitaria) has approved their leading-
edge technology for clinical use and commercialization in Brazil. Faxitron's
Intraoperative Specimen Radiography System, BioVision, and Stereotactic Core
Biopsy Specimen Radiography System, CoreVision, greatly enhance the standard
of patient care and improve operational efficiency in the diagnosis of breast
cancer.
Paul Murtagh, Faxitron’s CEO, stated: "The ANVISA medical device certification
allows us to play a central role in the critical ‘standard of care’ chain in breast
cancer. Our products enable radiologists and pathologists to diagnose more
quickly and surgeons to operate more efficiently. We are thrilled to be able to
bring our technology to Brazil to support opinion leading institutions and their
patients".
Brazil has the largest economy and medical device market in Latin America, and
there is an ever growing need for specialized imaging technology such as the
BioVision and CoreVision to improve the overall quality of care for the patients.
About Faxitron
Faxitron is the world’s largest and only fully vertically integrated, dedicated
cabinet x-ray company. With an installed base of over 7,000 systems in medical
facilities and scientific and industrial research laboratories around the globe,
Faxitron is the pioneer and industry standard in cabinet x-ray systems for
specimen radiography, research, and NDT applications. For more than 40 years,
Faxitron has defined cabinet x-ray by developing x-ray sensor technology and
innovative systems to meet the evolving needs of our customers. For more
information, please visit http://www.faxitron.com.
